Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Monday, May 27, 2024 for the Memorial Day holiday. Have a healthy, happy holiday.

Hide

Precision medicine solutions for solid tumors

Quest Diagnostics offers a comprehensive menu of solid tumor solutions. Our decision support tools help you find the best treatment plan, whether by aligning with standard of care and clinical trial options or by helping you navigate new and emerging therapies beyond current standards of care.

Comprehensive Genomic Profiling Pan-Cancer Panels

Our comprehensive, guideline-driven panels deliver insights to help you make treatment decisions based on the mutations found in the individual’s tumor sample. These panels can be helpful in determining eligibility in clinical studies.

The Solid Tumor Expanded Panel provides a comprehensive molecular profile that includes 500+ genes associated with a broad spectrum of cancers. This panel can be used for a comprehensive analysis of a patient’s genetic profile and contains clinically actionable genes as well as emerging genes.

The Solid Tumor Core Panel includes 49 genes and is designed to support physicians in choosing the most appropriate therapies for their patients based on the alterations found in the tumor sample DNA.
41776-pan-cancer.jpg

Here are some of the ways we’re helping to make solid tumor oncology testing more actionable and accessible:

Webinar now available

Precision Medicine: Your Role in Advancing the Future of Cancer Care
41776-webinar.jpg

Single-source solution for solid tumor laboratory diagnostics

Our goal is to provide 1 place for you to get trusted solid tumor insights. We continue to invest in our solid tumor testing solutions to build the broadest, most innovative portfolio in the industry.

Our approach combines extensive subspecialized expertise in pathology, cutting-edge technology, and a comprehensive test menu to provide new insights into diagnosis, prognosis, and treatment selection throughout a patient’s cancer journey.

With highly specialized testing technologies—including next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH)—we can help you get answers you can trust so you can make more informed decisions for patient care.

Our testing portfolio is based on clinically relevant and medically accepted guidelines (NCCN®, WHO, ACMG, AMP, IMWG, etc).

Over 400 board-certified and subspecialized pathologists in multiple cancers, including breast, gastrointestinal, gynecological, lung, and melanoma.

With state-of-the-art testing technologies, such as digital pathology, and the support of our board-certified pathologists and MDs, we’re committed to putting your patients first in everything we do.

White paper available

“Identifying genetic drivers of solid tumors”
41776-white-paper.jpg

Podcast available

Quest Diagnostics vision for genomics at scale
41776-podcast.jpg

Clincal conversation available

Precision medicine driven by precision diagnostics 
41776-clinical-conversation.jpg